Diagnosing early cognitive decline-When, how and for whom?

Charlotte L Allan1, Sophie Behrman2, Klaus P Ebmeier2

  • 1Centre for the Health of the Elderly, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle, UK.

Maturitas
|January 3, 2017
PubMed

Insights

Mild cognitive impairment (MCI) involves noticeable cognitive decline beyond normal aging, but not dementia. This review covers diagnosis, treatments, and legal issues for individuals experiencing early cognitive changes.

Area of Science:

  • Neurology
  • Geriatrics
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) signifies cognitive deficits exceeding age-expected changes, distinct from dementia.
  • Early identification of cognitive decline is crucial for timely intervention and management.
  • Understanding MCI is vital for addressing the growing needs of an aging global population.

Purpose of the Study:

  • To review diagnostic approaches for early cognitive decline, specifically mild cognitive impairment (MCI).
  • To explore available treatments and support systems for individuals with MCI.
  • To outline medico-legal considerations relevant to cognitive impairment.

Main Methods:

  • Review of current literature on mild cognitive impairment (MCI) diagnosis.
  • Analysis of neuropsychological tests and neuroimaging techniques for cognitive assessment.
  • Examination of treatment strategies and medico-legal implications.

Main Results:

  • Neuropsychological tests and neuroimaging are key tools for diagnosing MCI.
  • Differential diagnosis is essential to distinguish MCI from other conditions.
  • A range of treatments, including prevention and support, can be offered.
  • Medico-legal aspects impact daily life, including driving and employment.

Conclusions:

  • Accurate diagnosis of mild cognitive impairment (MCI) relies on comprehensive assessment.
  • Early intervention and ongoing support are vital for managing MCI.
  • Addressing medico-legal issues is a critical component of comprehensive MCI care.

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.0K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
633
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
776
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K